Literature DB >> 25941960

Spinal form cerebrotendinous xanthomatosis patient with long spinal cord lesion.

Ryuta Abe1, Yoshiki Sekijima1,2, Tomomi Kinoshita1, Tsuneaki Yoshinaga1, Shingo Koyama3, Takeo Kato3, Shu-Ichi Ikeda1,2.   

Abstract

CONTEXT: Cerebrotendinous xanthomatosis (CTX) is an autosomal recessively inherited lipid storage disease caused by mutation in the CYP27A1 gene. Spinal form CTX is a rare clinical subgroup of CTX and only 14 patients from 11 families have been reported to date. Here, we report the first Asian patient with spinal form CTX showing characteristic radiological findings.
FINDINGS: The patient, a 46-year-old Japanese male, developed sensory disturbance of the lower legs at 39 and spastic gait at 46 years of age. Spinal cord magnetic resonance imaging (MRI) revealed a long hyperintense lesion involving lateral corticospinal tracts and gracile tracts in the cervical and thoracic cord on T2-weighted images. Gallium-67 (67Ga) scintigraphy revealed abnormal uptake in the Achilles tendons and the serum cholestanol level was elevated. CYP27A1 gene analysis identified homozygous missense mutation, c.1214G>A (p.R405Q). The patient was treated with atorvastatin monotherapy, which reduced serum cholestanol to less than 50% of the pretreatment level.
CONCLUSION: Spinal form CTX should be considered in the differential diagnosis of cryptogenic myelopathy, especially in patients with a long spinal cord lesion, as treatment with chenodeoxycholic acid and/or competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase reverse the metabolic derangement and prevent the neurologiccal dysfunction.

Entities:  

Keywords:  CYP27A1gene; Cerebrotendinous xanthomatosis; Cholestanol; Long spinal cord lesion; Myelopathy

Mesh:

Substances:

Year:  2016        PMID: 25941960      PMCID: PMC5137569          DOI: 10.1179/1079026815Z.000000000409

Source DB:  PubMed          Journal:  J Spinal Cord Med        ISSN: 1079-0268            Impact factor:   1.985


  18 in total

1.  Three siblings with Cerebrotendinous Xanthomatosis: a novel mutation in the CYP27A1 gene.

Authors:  Sunghwan Suh; Hee Kyung Kim; Hyung-Doo Park; Chang-Seok Ki; Mi Yeon Kim; Sang-Man Jin; Se Won Kim; Kyu Yeon Hur; Kwang-Won Kim; Jae Hyeon Kim
Journal:  Eur J Med Genet       Date:  2011-09-16       Impact factor: 2.708

Review 2.  Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature.

Authors:  M Kuriyama; J Fujiyama; H Yoshidome; S Takenaga; K Matsumuro; T Kasama; K Fukuda; T Kuramoto; T Hoshita; Y Seyama
Journal:  J Neurol Sci       Date:  1991-04       Impact factor: 3.181

3.  Novel homozygous and compound heterozygous mutations of sterol 27-hydroxylase gene (CYP27) cause cerebrotendinous xanthomatosis in three Japanese patients from two unrelated families.

Authors:  W Chen; S Kubota; K S Kim; J Cheng; M Kuriyama; G Eggertsen; I Björkhem; Y Seyama
Journal:  J Lipid Res       Date:  1997-05       Impact factor: 5.922

4.  Cerebrotendinous xanthomatosis: biochemical response to inhibition of cholesterol synthesis.

Authors:  B Lewis; W D Mitchell; C B Marenah; C Cortese; E H Reynolds; R Shakir
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-02

5.  Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis.

Authors:  J J Cali; C L Hsieh; U Francke; D W Russell
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

6.  Clinical and radiological findings of a cerebrotendinous xanthomatosis patient with a novel p.A335V mutation in the CYP27A1 gene.

Authors:  Tsuneaki Yoshinaga; Yoshiki Sekijima; Shingo Koyama; Keiko Maruyama; Toshikazu Yoshida; Takeo Kato; Shu-ichi Ikeda
Journal:  Intern Med       Date:  2014-12-01       Impact factor: 1.271

7.  Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis.

Authors:  J J Cali; D W Russell
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

8.  A transferrin-mediated uptake of gallium-67 by EMT-6 sarcoma. II. Studies in vivo (BALB/c mice): concise communication.

Authors:  S M Larson; J S Rasey; D R Allen; Z Grunbaum
Journal:  J Nucl Med       Date:  1979-08       Impact factor: 10.057

9.  Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.

Authors:  T Nakamura; Y Matsuzawa; K Takemura; M Kubo; H Miki; S Tarui
Journal:  Metabolism       Date:  1991-07       Impact factor: 8.694

10.  Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.

Authors:  V M Berginer; G Salen; S Shefer
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

View more
  8 in total

1.  Nationwide survey on cerebrotendinous xanthomatosis in Japan.

Authors:  Yoshiki Sekijima; Shingo Koyama; Tsuneaki Yoshinaga; Masayoshi Koinuma; Yuji Inaba
Journal:  J Hum Genet       Date:  2018-01-10       Impact factor: 3.172

2.  Late-onset spinal form xanthomatosis without brain lesion: a case report.

Authors:  Masaru Yanagihashi; Osamu Kano; Tomoya Terashima; Yuji Kawase; Sayori Hanashiro; Masahiro Sawada; Yuichi Ishikawa; Nobuyuki Shiraga; Ken Ikeda; Yasuo Iwasaki
Journal:  BMC Neurol       Date:  2016-02-09       Impact factor: 2.474

3.  A Late-onset and Relatively Rapidly Progressive Case of Pure Spinal Form Cerebrotendinous Xanthomatosis with a Novel Mutation in the CYP27A1 Gene.

Authors:  Ken Takasone; Teruya Morizumi; Katsuya Nakamura; Yusuke Mochizuki; Tsuneaki Yoshinaga; Shingo Koyama; Yoshiki Sekijima
Journal:  Intern Med       Date:  2020-06-23       Impact factor: 1.271

4.  Spinal cerebrotendinous xanthomatosis: A case report and literature review.

Authors:  Isis Atallah; Diego San Millán; Wicki Benoît; Belinda Campos-Xavier; Andrea Superti-Furga; Christel Tran
Journal:  Mol Genet Metab Rep       Date:  2021-02-03

5.  Cerebrotendinous xanthomatosis with peripheral neuropathy: a clinical and neurophysiological study in Chinese population.

Authors:  Shu Zhang; Wei Li; Rui Zheng; Bing Zhao; Yongqing Zhang; Dandan Zhao; Cuiping Zhao; Chuanzhu Yan; Yuying Zhao
Journal:  Ann Transl Med       Date:  2020-11

Review 6.  The clinical and imaging features of cerebrotendinous xanthomatosis: A case report and review of the literature.

Authors:  Chi Ma; Yan-De Ren; Jia-Chen Wang; Cheng-Jian Wang; Ji-Ping Zhao; Tong Zhou; Hua-Wei Su
Journal:  Medicine (Baltimore)       Date:  2021-03-05       Impact factor: 1.817

7.  Achilles swelling and ataxia in an adolescent: A case report of cerebrotendinous xanthomatosis.

Authors:  Hind Sahli; Jihane El Mandour; Jihad Boularab; Issam En-Nafaa; Jamal El Fenni; Aziz Hommadi
Journal:  Radiol Case Rep       Date:  2022-01-13

8.  Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.

Authors:  Shingo Koyama; Yoshiki Sekijima; Masatsune Ogura; Mika Hori; Kota Matsuki; Takashi Miida; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-08       Impact factor: 4.928

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.